34.43 USD
-0.07 (-0.2%)
34.43 USD
0 (0%)
Overall AZTA gets a fundamental rating of 4 out of 10. We evaluated AZTA against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for AZTA as it has an excellent financial health rating, but there are worries on the profitability. AZTA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AZTA had positive earnings in the past year.
AZTA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: AZTA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: AZTA reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -5.53%, AZTA perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
AZTA's Return On Equity of -6.67% is in line compared to the rest of the industry. AZTA outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -6.67% | ||
| ROIC | N/A |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AZTA (44.92%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of AZTA has remained more or less at the same level.
AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AZTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AZTA has an Altman-Z score of 4.19. This indicates that AZTA is financially healthy and has little risk of bankruptcy at the moment.
AZTA's Altman-Z score of 4.19 is fine compared to the rest of the industry. AZTA outperforms 75.44% of its industry peers.
There is no outstanding debt for AZTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.19 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 2.76 indicates that AZTA has no problem at all paying its short term obligations.
AZTA's Current ratio of 2.76 is in line compared to the rest of the industry. AZTA outperforms 50.88% of its industry peers.
AZTA has a Quick Ratio of 2.44. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
AZTA's Quick ratio of 2.44 is in line compared to the rest of the industry. AZTA outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.27%, which is quite impressive.
The earnings per share for AZTA have been decreasing by -16.04% on average. This is quite bad
EPS 1Y (TTM)29.27%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.39%
3.2 Future
The Earnings Per Share is expected to grow by 27.49% on average over the next years. This is a very strong growth
AZTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.37% yearly.
EPS Next Y50.94%
EPS Next 2Y39.87%
EPS Next 3Y32.3%
EPS Next 5Y27.49%
Revenue Next Year4.54%
Revenue Next 2Y4.78%
Revenue Next 3Y4.73%
Revenue Next 5Y5.37%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 64.96 indicates a quite expensive valuation of AZTA.
Compared to the rest of the industry, the Price/Earnings ratio of AZTA is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.38, AZTA is valued quite expensively.
AZTA is valuated quite expensively with a Price/Forward Earnings ratio of 43.04.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AZTA indicates a somewhat cheap valuation: AZTA is cheaper than 61.40% of the companies listed in the same industry.
AZTA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.96 | ||
| Fwd PE | 43.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AZTA is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, AZTA is valued a bit cheaper than the industry average as 70.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.57 | ||
| EV/EBITDA | 33.5 |
4.3 Compensation for Growth
AZTA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZTA's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.28
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y32.3%
5. Dividend
5.1 Amount
AZTA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
34.43
-0.07 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners110.87%
Inst Owner ChangeN/A
Ins Owners1.07%
Ins Owner Change11.23%
Market Cap1.58B
Revenue(TTM)N/A
Net Income(TTM)-111.59M
Analysts75.71
Price Target39.34 (14.26%)
Short Float %7.52%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.12%
Min EPS beat(2)-29.97%
Max EPS beat(2)36.22%
EPS beat(4)3
Avg EPS beat(4)28.83%
Min EPS beat(4)-29.97%
Max EPS beat(4)71.81%
EPS beat(8)7
Avg EPS beat(8)146.76%
EPS beat(12)10
Avg EPS beat(12)157.49%
EPS beat(16)13
Avg EPS beat(16)123.07%
Revenue beat(2)0
Avg Revenue beat(2)-2.89%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)-0.22%
Revenue beat(4)0
Avg Revenue beat(4)-2.14%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)-0.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.7%
PT rev (1m)15.88%
PT rev (3m)22.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.96 | ||
| Fwd PE | 43.04 | ||
| P/S | 2.61 | ||
| P/FCF | 34.57 | ||
| P/OCF | 18.86 | ||
| P/B | 0.94 | ||
| P/tB | 1.83 | ||
| EV/EBITDA | 33.5 |
EPS(TTM)0.53
EY1.54%
EPS(NY)0.8
Fwd EY2.32%
FCF(TTM)1
FCFY2.89%
OCF(TTM)1.83
OCFY5.3%
SpS13.19
BVpS36.49
TBVpS18.79
PEG (NY)1.28
PEG (5Y)N/A
Graham Number20.86
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -6.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.92% | ||
| FCFM | 7.55% |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 53.88% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 231.56% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 4.19 |
F-Score7
WACC10.4%
ROIC/WACCN/A
Cap/Depr(3y)77.14%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.52%
Cap/Sales(5y)9.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.27%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%16.67%
EPS Next Y50.94%
EPS Next 2Y39.87%
EPS Next 3Y32.3%
EPS Next 5Y27.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.39%
Revenue Next Year4.54%
Revenue Next 2Y4.78%
Revenue Next 3Y4.73%
Revenue Next 5Y5.37%
EBIT growth 1Y55.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1008.67%
EBIT Next 3Y156.86%
EBIT Next 5Y106.78%
FCF growth 1Y182.14%
FCF growth 3Y-48.98%
FCF growth 5Y-28.07%
OCF growth 1Y759.23%
OCF growth 3Y-30.52%
OCF growth 5Y-11.17%
AZENTA INC / AZTA FAQ
Can you provide the ChartMill fundamental rating for AZENTA INC?
ChartMill assigns a fundamental rating of 4 / 10 to AZTA.
Can you provide the valuation status for AZENTA INC?
ChartMill assigns a valuation rating of 4 / 10 to AZENTA INC (AZTA). This can be considered as Fairly Valued.
How profitable is AZENTA INC (AZTA) stock?
AZENTA INC (AZTA) has a profitability rating of 2 / 10.
What is the financial health of AZENTA INC (AZTA) stock?
The financial health rating of AZENTA INC (AZTA) is 7 / 10.
Is the dividend of AZENTA INC sustainable?
The dividend rating of AZENTA INC (AZTA) is 0 / 10 and the dividend payout ratio is 0%.